Cytokine networks in glioma
- PMID: 21656131
- DOI: 10.1007/s10143-011-0320-y
Cytokine networks in glioma
Abstract
Glioma is the most frequently occurring brain tumor, but the prognosis of patients with gliomas remains poor despite advances in surgery, radiotherapy, and chemotherapy. Therefore, great efforts have been made to develop improved therapeutic strategies. Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins that exert pleiotropic and redundant effects that promote the growth, differentiation, and activation of normal cells. Cytokines have either pro- or anti-inflammatory activity and immunosuppressive activity, depending on the microenvironment surrounding the tumor. The microenvironment consists of heterogeneous tumor cells, immune cells, and extracellular matrix. Modulation of the microenvironment by the tumor is essential for its growth and progress. Cytokine production acts as a means of communication in the tumor microenvironment. In this article, we review the cross-talk between cytokines in the tumor microenvironment and the cytokine therapies that have been used till date for glioma treatment.
Similar articles
-
Cytokine therapy.Adv Exp Med Biol. 2012;746:86-94. doi: 10.1007/978-1-4614-3146-6_7. Adv Exp Med Biol. 2012. PMID: 22639161 Review.
-
Cytokine Therapy of Gliomas.Prog Neurol Surg. 2018;32:79-89. doi: 10.1159/000469682. Epub 2018 Jul 10. Prog Neurol Surg. 2018. PMID: 29990976 Review.
-
Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle.Biochim Biophys Acta. 2014 Dec;1846(2):560-75. doi: 10.1016/j.bbcan.2014.10.003. Epub 2014 Oct 20. Biochim Biophys Acta. 2014. PMID: 25453365 Review.
-
Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain.Int Rev Neurobiol. 2020;151:253-279. doi: 10.1016/bs.irn.2020.03.027. Epub 2020 May 13. Int Rev Neurobiol. 2020. PMID: 32448611
-
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.J Neurooncol. 2020 Apr;147(2):281-295. doi: 10.1007/s11060-020-03450-7. Epub 2020 Mar 17. J Neurooncol. 2020. PMID: 32185647 Free PMC article. Review.
Cited by
-
Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.Tumour Biol. 2012 Oct;33(5):1477-84. doi: 10.1007/s13277-012-0398-z. Epub 2012 Apr 29. Tumour Biol. 2012. PMID: 22544614
-
Perspective on Translating Biomaterials Into Glioma Therapy: Lessons From in vitro Models.Front Mater. 2018 May;5:27. doi: 10.3389/fmats.2018.00027. Epub 2018 May 9. Front Mater. 2018. PMID: 30911536 Free PMC article.
-
Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications.Cancers (Basel). 2021 Aug 23;13(16):4226. doi: 10.3390/cancers13164226. Cancers (Basel). 2021. PMID: 34439380 Free PMC article. Review.
-
Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells.Tumour Biol. 2012 Dec;33(6):2255-63. doi: 10.1007/s13277-012-0487-z. Epub 2012 Aug 23. Tumour Biol. 2012. PMID: 22915266
-
Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.PLoS One. 2015 May 15;10(5):e0126022. doi: 10.1371/journal.pone.0126022. eCollection 2015. PLoS One. 2015. PMID: 25978454 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical